IMUGENE

Developing Cancer Immunotherapies

EXTRAORDINARY GENERAL MEETING

Wednesday, 22 January 2025

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited

Company Overview

IMUGENE
Developing Cancer Immunotherapies

Imugene is a clinical-stage immuno-oncology company developing a range of novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors

3 PLATFORM TECHNOLOGIES
In cell therapy, oncolytic virus & innovative combination applications

- Allo CAR T Cell Therapy
- CF33 Oncolytic Virus
- onCARlytics

A$306M
Market Capitalization
As of Jan. 20, 2025

3 CLINICAL STUDIES
in US and AUS, all under INDs (IMU sponsored)

>200 PATIENTS DOSED
with clinical data readouts over next year

A$54.3M
Cash Position
As of Sept. 30, 2024
(+ A$11.7m R&D rebate received Jan 2025)

EGM – Market Update

IMUGENE
Developing Cancer Immunotherapies

Financial Summary

Convertible bond and warrant facility with CVI Investments Inc. for up to $46 million, with $20 million immediately following today's EGM

Up to an additional $26 million if warrants are exercised over the next 5 years

$11.7 million R&D rebate received on the 10th of January 2025

Careful review of operating costs and overheads continues throughout 2025

Streamlining manufacturing operations, optimizing workforce levels, and reducing administrative overheads, extending the cash runway to end of 2025, excluding exercise of warrants

67% Complete Response Rates Observed in Phase 1b Cohort B

Allo CAR T Cell Therapy
IMUGENE



	Evaluable patients: Cohort A+B (N=9)	Evaluable patients: Cohort A (N=6)	Evaluable patients: Cohort B (N=3)
Overall Response Rate %	4 (44%)	2 (33%)	2 (67%)
Complete Response %	3 (33%)	1 (17%)	2 (67%)
Best Durability (Time of response)		<60 days	>120 days on going

Responses were seen in patients who failed multiple prior treatments, including autologous CAR T therapies

azer-cel:

- 15 active US sites & 1 activated in Australia (1 of 5)
- First Australian DLBCL (Diffused Large B-Cell Lymphoma) patient dosed at Royal Prince Alfred Hospital in Sydney.
- Abstract accepted for Transplantation and Cellular Therapy Meeting February 2025

[1]Lymphodepletion(LD)/chemotherapy: Aug Cy: Flu 30mg/m2 x 3d, Cy 750mg/m2 x 3d

Phase 1 MAST Trial – Encouraging Early Signals

CF33 Oncolytic Virus
IMUGENE

Patients[1]
- >40 patients have been dosed and evaluated (at least their first scan at day 42)

Disease Control So Far
- Nearly half of the evaluable patients (48%) have remained on treatment for >3 months
- 3 patients have remained on treatment for >200 days

Responses
- Patient with bile tract cancer who had a complete response (CR); ongoing remission for **>2 years**
- 2 patients with melanoma had partial responses (PRs); 17 patients achieved stable disease (SD)

Bile Tract Trial
- Bile tract cancer expansion trial opened based on positive response
- First cohort cleared, establishing safety

Fast Track and Orphan Drug Designation
- US FDA Fast Track Designation for bile tract cancer, which allows for faster review
- US FDA Orphan Drug Designation for bile tract cancer, which allows for further efficiencies

2025 Key Catalysts
- CF33-PD-1 abstract accepted for AACR Immuno-oncology meeting (February 2025)
- Optimal Biological Dose Established in 2025
- Continue to provide status update and Phase 2 Start Up Activity

ST VINCENT'S HOSPITAL MELBOURNE
A FACILITY OF ST VINCENT'S HEALTH AUSTRALIA

Karmanos CANCER INSTITUTE

HIGHLANDS ONCOLOGY

City of Hope

Cancer Center

UNIVERSITY OF UTAH HUNTSMAN CANCER INSTITUTE

U.S. FOOD & DRUG ADMINISTRATION

FAST TRACK Designation

Orphan Drug Designation

[1]Preliminary study update as of June 2024; data and number of evaluable patients subject to change with full statistical analysis

Imugene Has Initiated The OASIS Phase 1 Open Label Trial with CD19 Virus and Blinatumomab

onCARlytics IMUGENE

Combination treatment for solid cancers

onCARlytics

onCARlytics CD19 virus

+

CD19 Bispecific antibody

Recruiting up to 40 patients

First patient dosed July 2023 at City of Hope

Multiple trial sites including; University of Cincinnati, MD Anderson Cancer Centre and City of Hope

onCARlytics: Extensive Possibilities

Solid tumors, which lack CD19, represent

~90% of the cancer market.

onCARlytics can become the preferred partner for opening this market to CD19-targeting therapies



Combination Opportunities

Company	Product	Target	Indications	First FDA Approval
NOVARTIS	KYMRIAH (tisagenlecleucel)	CD19 Auto CAR T	B-ALL, DLBCL	2017
GILEAD	YESCARTA (axicabtagene ciloleucel)	CD19 Auto CAR T	DLBCL, R/R FL	2017
	TECARTUS (brexucabtagene autoleucel)	CD19 Auto CAR T	R/R MCL	2020
Bristol Myers Squibb	Breyanzi (lisocabtagene maraleucel)	CD19 Auto CAR T	DLBCL	2021
Incyte	MONJUVI tafasitamab-cxix	CD19 Monoclonal Antibodies (MAbs)	DLBCL	2020
HORIZON	uplizna inebilizumab-cdon	CD19 MAbs	NMOSD	2020
AMGEN	BLINCYTO (blinatumomab)	CD19-CD3 Bispecific MAbs	ALL	2014
ADC THERAPEUTICS	zynlonta loncastuximab tesirine-lpyl	CD19 Antibody-Drug Conjugate (ADC)	B-Cell Lymphoma	2021

1. https://www.precedenceresearch.com/solid-tumor-cancer-treatment-market

2024 Highlights And Expected Upcoming Key Catalysts

IMUGENE
Developing Cancer Immunotherapies

Program	2024		2025	
	1H	2H	1H	2H
azer-cel (CD19 CAR T)	• 3 CRs in Phase 1b DLBCL trial	• Preliminary early DLBCL Phase 1b data update • First AUS site open for Phase 1b clinical trial	• First patient dosed in AUS • Orphan Drug Designation/ Fast Track Designation	• Expansion into additional blood cancers (Phase 1b Expansion Cohorts) • Phase 1b data update
VAXINIA (CF33)	• 1 CR (in remission for >2 yrs), 2 PRs in MAST trial All treatments safe & tolerable	• Bile Tract cancer expansion trial open, first cohort cleared • Orphan Drug Designation received • Second indication: NMIBC cohort open	• Data update	• OBD established for IT and/or IV monotherapy • Phase 2 start-up
onCARlytics (CF33-CD19)	• OASIS IV and IT Monotherapy cohort cleared • OASIS Combination arm open, FPI in IV and IT Combo	• FPI IT Combo Cohort 1	• Early IT and/or IV Combo data	• FPI IT Combo Cohort 2

DLBCL: Diffuse Large B-Cell Lymphoma (Blood Cancer)
NMIBC: Non-muscle invasive bladder cancer
CR: Complete Response
PR: Partial Response

FPI: First Patient In
Combo: Combination Therapy, **Mono**: Monotherapy
IT: Intratumoral, **IV**: Intravenous
OBD: Optimal Biological Dose

Transformative Cancer Therapies To Watch In 2025

IMUGENE
Developing Cancer Immunotherapies

POSSIBILITIES AND PROMISE FOR 2025 & BEYOND
Stay tuned...

- Encouraging results in three novel programs, with expansions into new indications
- Addressing unmet patient needs, with significant available markets and growth potential
- Extensive safety data
- Expecting readouts and milestones in next 12+ months
- Strong market cap and cash position

Allo CAR T Cell Therapy
IMUGENE

- Option for fast-growing cohort of autologous CD19 CAR T relapse patients with blood cancers
- "Off-the-shelf" allogenic therapy offers broader patient access, better safety profile and more efficient manufacturing
- Evaluating next-generation allogenic cell therapy candidates

CF33 Oncolytic Virus
IMUGENE

- Solid tumor-agnostic approach
- Multiple cancer cell-killing activities
- Targeted infection and replication in cancer cells

onCARlytics
IMUGENE

- Inverts precision medicine by matching the tumor to the therapy
- Two-pronged attack on tumors in combination with multiple CD19-targeting therapies
- Potential to open vast solid tumor market to CD19-targeting therapies

ASX : IMU

shareholderenquiries@imugene.com
imugene.com

IMUGENE
Developing Cancer Immunotherapies